Logo image of INDP

INDAPTUS THERAPEUTICS INC (INDP) Stock Fundamental Analysis

NASDAQ:INDP - Nasdaq - US45339J1051 - Common Stock - Currency: USD

0.2701  -0.06 (-17.9%)

After market: 0.2877 +0.02 (+6.52%)

Fundamental Rating

2

Taking everything into account, INDP scores 2 out of 10 in our fundamental rating. INDP was compared to 558 industry peers in the Biotechnology industry. The financial health of INDP is average, but there are quite some concerns on its profitability. INDP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year INDP has reported negative net income.
In the past year INDP has reported a negative cash flow from operations.
In the past 5 years INDP always reported negative net income.
INDP had a negative operating cash flow in each of the past 5 years.
INDP Yearly Net Income VS EBIT VS OCF VS FCFINDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

INDP has a worse Return On Assets (-291.00%) than 93.18% of its industry peers.
INDP has a worse Return On Equity (-562.48%) than 79.53% of its industry peers.
Industry RankSector Rank
ROA -291%
ROE -562.48%
ROIC N/A
ROA(3y)-119.69%
ROA(5y)-89.14%
ROE(3y)-188.88%
ROE(5y)-137.07%
ROIC(3y)N/A
ROIC(5y)N/A
INDP Yearly ROA, ROE, ROICINDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INDP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INDP Yearly Profit, Operating, Gross MarginsINDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, INDP has more shares outstanding
Compared to 5 years ago, INDP has more shares outstanding
There is no outstanding debt for INDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INDP Yearly Shares OutstandingINDP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
INDP Yearly Total Debt VS Total AssetsINDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -25.05, we must say that INDP is in the distress zone and has some risk of bankruptcy.
INDP's Altman-Z score of -25.05 is on the low side compared to the rest of the industry. INDP is outperformed by 87.79% of its industry peers.
There is no outstanding debt for INDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -25.05
ROIC/WACCN/A
WACCN/A
INDP Yearly LT Debt VS Equity VS FCFINDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

INDP has a Current Ratio of 1.90. This is a normal value and indicates that INDP is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.90, INDP is not doing good in the industry: 77.74% of the companies in the same industry are doing better.
INDP has a Quick Ratio of 1.90. This is a normal value and indicates that INDP is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.90, INDP is not doing good in the industry: 76.66% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.9
Quick Ratio 1.9
INDP Yearly Current Assets VS Current LiabilitesINDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

1

3. Growth

3.1 Past

INDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.76%, which is quite good.
EPS 1Y (TTM)16.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 33.03% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.26%
EPS Next 2Y26.62%
EPS Next 3Y17.04%
EPS Next 5Y33.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INDP Yearly Revenue VS EstimatesINDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2028 2029 2030 2031 2032 100M 200M 300M
INDP Yearly EPS VS EstimatesINDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80 -100

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INDP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INDP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INDP Price Earnings VS Forward Price EarningsINDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INDP Per share dataINDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as INDP's earnings are expected to grow with 17.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.62%
EPS Next 3Y17.04%

0

5. Dividend

5.1 Amount

No dividends for INDP!.
Industry RankSector Rank
Dividend Yield N/A

INDAPTUS THERAPEUTICS INC

NASDAQ:INDP (6/20/2025, 8:00:02 PM)

After market: 0.2877 +0.02 (+6.52%)

0.2701

-0.06 (-17.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)N/A N/A
Inst Owners13.08%
Inst Owner Change7.64%
Ins Owners30.19%
Ins Owner Change0%
Market Cap4.33M
Analysts82.86
Price Target7.14 (2543.47%)
Short Float %10.13%
Short Ratio2.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.48%
Min EPS beat(2)-74.29%
Max EPS beat(2)15.33%
EPS beat(4)3
Avg EPS beat(4)-2.76%
Min EPS beat(4)-74.29%
Max EPS beat(4)33.25%
EPS beat(8)7
Avg EPS beat(8)9.34%
EPS beat(12)11
Avg EPS beat(12)11.28%
EPS beat(16)13
Avg EPS beat(16)6.68%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.65%
PT rev (3m)-17.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)30.91%
EPS NY rev (1m)0%
EPS NY rev (3m)27.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.55
P/tB 1.55
EV/EBITDA N/A
EPS(TTM)-1.49
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS0
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -291%
ROE -562.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-119.69%
ROA(5y)-89.14%
ROE(3y)-188.88%
ROE(5y)-137.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.9
Quick Ratio 1.9
Altman-Z -25.05
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.89%
EPS Next Y50.26%
EPS Next 2Y26.62%
EPS Next 3Y17.04%
EPS Next 5Y33.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.96%
OCF growth 3YN/A
OCF growth 5YN/A